Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310735420> ?p ?o ?g. }
- W4310735420 endingPage "174.e10" @default.
- W4310735420 startingPage "174.e1" @default.
- W4310735420 abstract "For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care includes induction therapy followed by autologous stem cell transplantation (ASCT). Daratumumab as monotherapy and in combination treatment is approved across multiple lines of therapy for multiple myeloma (MM), and lenalidomide is an effective and commonly used agent for induction and maintenance therapy in MM. However, there is concern that lenalidomide and daratumumab given as induction therapy might impair mobilization of stem cells for ASCT. Therefore, we assessed stem cell mobilization in patients following frontline induction therapy in the MASTER and GRIFFIN phase 2 clinical studies by examining stem cell mobilization yields, apheresis attempts, and engraftment outcomes for patients from each study. Adult transplantation-eligible patients with NDMM received induction therapy consisting of daratumumab plus carfilzomib/lenalidomide/dexamethasone (D-KRd) for four 28-day cycles in the single-arm MASTER trial or lenalidomide/bortezomib/dexamethasone (RVd) with or without daratumumab (D) for four 21-day cycles in the randomized GRIFFIN trial, followed by stem cell mobilization and ASCT in both studies. Institutional practice differed regarding plerixafor use for stem cell mobilization; the strategies were upfront (ie, planned plerixafor use) or rescue (ie, plerixafor use only after mobilization parameters indicated failure with granulocyte colony-stimulating factor [G-CSF] alone). Descriptive analyses were used to summarize patient characteristics, stem cell mobilization yields, and engraftment outcomes. In MASTER, 116 D-KRd recipients underwent stem cell mobilization and collection at a median of 24 days after completing induction therapy. In GRIFFIN, 175 patients (D-RVd, n = 95; RVd, n = 80) underwent mobilization at a median of 27 days after completing D-RVd induction therapy and 24 days after completing RVd induction therapy. Among those who underwent mobilization and collection, 7% (8 of 116) of D-KRd recipients, 2% (2 of 95) of D-RVd recipients, and 6% (5 of 80) of RVd recipients did not meet the center-specific minimally required CD34+ cell yield in the first mobilization attempt; however, nearly all collected sufficient stem cells for ASCT on remobilization. Among patients who underwent mobilization, plerixafor use, either upfront or as a rescue strategy, was higher in patients receiving D-KRd (97%; 112 of 116) and D-RVd (72%; 68 of 95) compared with those receiving RVd (55%; 44 of 80). The median total CD34+ cell collection was 6.0 × 106/kg (range, 2.2 to 13.9 × 106/kg) after D-KRd induction, 8.3 × 106/kg (range, 2.6 to 33.0 × 106/kg) after D-RVd induction, and 9.4 × 106/kg (range, 4.1 to 28.7 × 106/kg) after RVd induction; the median days for collection were 2, 2, and 1, respectively. Among patients who underwent mobilization, 98% (114 of 116) of D-KRd patients, 99% (94 of 95) of D-RVd patients, and 98% (78 of 80) of RVd patients underwent ASCT using median CD34+ cell doses of 3.2 × 106/kg, 4.2 × 106/kg, and 4.8 × 106/kg, respectively. The median time to neutrophil recovery was 12 days in all 3 treatment groups across the 2 trials. Because both trials used different criteria to define platelet recovery, data on platelet engraftment using the same criteria are not available. Four cycles of daratumumab- and lenalidomide-based quadruplet induction therapy had a minimal impact on stem cell mobilization and allowed predictable stem cell harvesting and engraftment in all patients who underwent ASCT. Upfront plerixafor strategy may be considered, but many patients were successfully collected with the use of G-CSF alone or rescue plerixafor." @default.
- W4310735420 created "2022-12-16" @default.
- W4310735420 creator A5003805183 @default.
- W4310735420 creator A5005732386 @default.
- W4310735420 creator A5005850190 @default.
- W4310735420 creator A5006108161 @default.
- W4310735420 creator A5009378735 @default.
- W4310735420 creator A5024384857 @default.
- W4310735420 creator A5026731813 @default.
- W4310735420 creator A5026804242 @default.
- W4310735420 creator A5028564534 @default.
- W4310735420 creator A5033256635 @default.
- W4310735420 creator A5038235561 @default.
- W4310735420 creator A5039067043 @default.
- W4310735420 creator A5039679523 @default.
- W4310735420 creator A5040738036 @default.
- W4310735420 creator A5042432109 @default.
- W4310735420 creator A5043526996 @default.
- W4310735420 creator A5044606180 @default.
- W4310735420 creator A5046784010 @default.
- W4310735420 creator A5047122777 @default.
- W4310735420 creator A5049711954 @default.
- W4310735420 creator A5050097218 @default.
- W4310735420 creator A5053572690 @default.
- W4310735420 creator A5053731124 @default.
- W4310735420 creator A5053904944 @default.
- W4310735420 creator A5055922112 @default.
- W4310735420 creator A5057911528 @default.
- W4310735420 creator A5058783159 @default.
- W4310735420 creator A5065188588 @default.
- W4310735420 creator A5071438752 @default.
- W4310735420 creator A5072909957 @default.
- W4310735420 creator A5078774694 @default.
- W4310735420 creator A5082072227 @default.
- W4310735420 creator A5083818486 @default.
- W4310735420 creator A5084990947 @default.
- W4310735420 creator A5089064532 @default.
- W4310735420 creator A5090375120 @default.
- W4310735420 creator A5091600784 @default.
- W4310735420 date "2023-03-01" @default.
- W4310735420 modified "2023-10-10" @default.
- W4310735420 title "Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials" @default.
- W4310735420 cites W1982891791 @default.
- W4310735420 cites W1983774108 @default.
- W4310735420 cites W1988715082 @default.
- W4310735420 cites W2008510614 @default.
- W4310735420 cites W2009443185 @default.
- W4310735420 cites W2013741276 @default.
- W4310735420 cites W2020445243 @default.
- W4310735420 cites W2036985459 @default.
- W4310735420 cites W2068635884 @default.
- W4310735420 cites W2084084240 @default.
- W4310735420 cites W2085269642 @default.
- W4310735420 cites W2102591890 @default.
- W4310735420 cites W2107057207 @default.
- W4310735420 cites W2121735943 @default.
- W4310735420 cites W2144728882 @default.
- W4310735420 cites W2193716145 @default.
- W4310735420 cites W2509480048 @default.
- W4310735420 cites W2512106959 @default.
- W4310735420 cites W2897332653 @default.
- W4310735420 cites W2921533600 @default.
- W4310735420 cites W2944739652 @default.
- W4310735420 cites W2948728876 @default.
- W4310735420 cites W3019889711 @default.
- W4310735420 cites W3049464285 @default.
- W4310735420 cites W3126448828 @default.
- W4310735420 cites W3133800890 @default.
- W4310735420 cites W3145716452 @default.
- W4310735420 cites W3164708987 @default.
- W4310735420 cites W3170038569 @default.
- W4310735420 cites W3172124846 @default.
- W4310735420 doi "https://doi.org/10.1016/j.jtct.2022.11.029" @default.
- W4310735420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36494017" @default.
- W4310735420 hasPublicationYear "2023" @default.
- W4310735420 type Work @default.
- W4310735420 citedByCount "5" @default.
- W4310735420 countsByYear W43107354202023 @default.
- W4310735420 crossrefType "journal-article" @default.
- W4310735420 hasAuthorship W4310735420A5003805183 @default.
- W4310735420 hasAuthorship W4310735420A5005732386 @default.
- W4310735420 hasAuthorship W4310735420A5005850190 @default.
- W4310735420 hasAuthorship W4310735420A5006108161 @default.
- W4310735420 hasAuthorship W4310735420A5009378735 @default.
- W4310735420 hasAuthorship W4310735420A5024384857 @default.
- W4310735420 hasAuthorship W4310735420A5026731813 @default.
- W4310735420 hasAuthorship W4310735420A5026804242 @default.
- W4310735420 hasAuthorship W4310735420A5028564534 @default.
- W4310735420 hasAuthorship W4310735420A5033256635 @default.
- W4310735420 hasAuthorship W4310735420A5038235561 @default.
- W4310735420 hasAuthorship W4310735420A5039067043 @default.
- W4310735420 hasAuthorship W4310735420A5039679523 @default.
- W4310735420 hasAuthorship W4310735420A5040738036 @default.
- W4310735420 hasAuthorship W4310735420A5042432109 @default.
- W4310735420 hasAuthorship W4310735420A5043526996 @default.
- W4310735420 hasAuthorship W4310735420A5044606180 @default.
- W4310735420 hasAuthorship W4310735420A5046784010 @default.
- W4310735420 hasAuthorship W4310735420A5047122777 @default.